仙琚制药：阿更葡糖钠注射液处于上市销售前的符合性检查阶段

证券之星08-20

证券之星消息，仙琚制药(002332)08月20日在投资者关系平台上答复投资者关心的问题。

投资者提问：董秘您好，关注到公司高端制剂募资项目土建已完成，设备安装调试基本结束，同时阿更葡糖钠注射液（奥美克松钠）已于今年7月获批上市，请问：1.高端制剂项目预计何时完成工艺验证并正式投产？2.奥美克松钠获批后目前商业化生产准备进展如何预计何时实现批量供货？3.公司已授权爱施健作为独家推广服务商请问首批铺货计划覆盖哪些区域？谢谢。

仙琚制药回复：您好！感谢您的关注。公司高端制剂项目部分产品正在申报审批阶段。据了解，阿更葡糖钠注射液（奥美克松钠注射液）处于上市销售前的符合性检查阶段，谢谢。

本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。

责任编辑：刘浩然

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/2660026264?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-20 16:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2660026264","market":"sh","top_or_hot":-1,"title":"仙琚制药：阿更葡糖钠注射液处于上市销售前的符合性检查阶段","media":"证券之星","content":"<html><body><p>证券之星消息，<a href=\"https://laohu8.com/S/002332\">仙琚制药</a>(002332)08月20日在投资者关系平台上答复投资者关心的问题。</p><p>投资者提问：董秘您好，关注到公司高端制剂募资项目土建已完成，设备安装调试基本结束，同时阿更葡糖钠注射液（奥美克松钠）已于今年7月获批上市，请问：1.高端制剂项目预计何时完成工艺验证并正式投产？2.奥美克松钠获批后目前商业化生产准备进展如何预计何时实现批量供货？3.公司已授权爱施健作为独家推广服务商请问首批铺货计划覆盖哪些区域？谢谢。</p><p>仙琚制药回复：您好！感谢您的关注。公司高端制剂项目部分产品正在申报审批阶段。据了解，阿更葡糖钠注射液（奥美克松钠注射液）处于上市销售前的符合性检查阶段，谢谢。</p><p>本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。</p><p>责任编辑：刘浩然</p></body></html>","source":"stockstar","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>仙琚制药：阿更葡糖钠注射液处于上市销售前的符合性检查阶段</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n仙琚制药：阿更葡糖钠注射液处于上市销售前的符合性检查阶段\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-08-20 16:30 北京时间&nbsp;&nbsp;&nbsp;<a href=https://stock.stockstar.com/RB2026082000028697.shtml><strong>证券之星</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>证券之星消息，仙琚制药(002332)08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，关注到公司高端制剂募资项目土建已完成，设备安装调试基本结束，同时阿更葡糖钠注射液（奥美克松钠）已于今年7月获批上市，请问：1.高端制剂项目预计何时完成工艺验证并正式投产？2.奥美克松钠获批后目前商业化生产准备进展如何预计何时实现批量供货？3.公司已授权爱施健作为独家推广服务商请问首批铺货...</p>\n\n<a href=\"https://stock.stockstar.com/RB2026082000028697.shtml\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"002332","symbol_name":"仙琚制药","start_time":0,"source_url":"https://stock.stockstar.com/RB2026082000028697.shtml","article_id":"2660026264","we_media_id":"1082532455","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2660026264","pubTimestamp":1787214627,"columns":[],"sourceInfo":{"source_id":"stockstar","name":"证券之星"},"weMediaInfo":{"media_name":"证券之星","introduction":"证券之星始创于1996年，是国内领先的金融信息及综合服务平台。关注证券之星，即时获取有价值的财经资讯。","home_visible":1,"id":"1082532455","head_image":"https://community-static.tradeup.com/news/2e305640fc27210243042d09d3a7fa3f"},"summary":"证券之星消息，仙琚制药08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，关注到公司高端制剂募资项目土建已完成，设备安装调试基本结束，同时阿更葡糖钠注射液已于今年7月获批上市，请问：1.高端制剂项目预计何时完成工艺验证并正式投产？据了解，阿更葡糖钠注射液处于上市销售前的符合性检查阶段，谢谢。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"002332":"仙琚制药","SG9999014674.SGD":"Nikko AM All China Equity A SGD","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"Xianju Pharmaceutical: Agenglucose Sodium Injection is in the compliance inspection stage before marketing","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"002332":1.5},"content_text":"证券之星消息，仙琚制药(002332)08月20日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘您好，关注到公司高端制剂募资项目土建已完成，设备安装调试基本结束，同时阿更葡糖钠注射液（奥美克松钠）已于今年7月获批上市，请问：1.高端制剂项目预计何时完成工艺验证并正式投产？2.奥美克松钠获批后目前商业化生产准备进展如何预计何时实现批量供货？3.公司已授权爱施健作为独家推广服务商请问首批铺货计划覆盖哪些区域？谢谢。仙琚制药回复：您好！感谢您的关注。公司高端制剂项目部分产品正在申报审批阶段。据了解，阿更葡糖钠注射液（奥美克松钠注射液）处于上市销售前的符合性检查阶段，谢谢。本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2660026264","isCrawlerRequest":true}